ReviewCancers2023

Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?

Estelle Granet-Vaissiere et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.